Decellularised Extracellular Carpets for the Innovative Production of Human Engineered Replicates

Informazioni relative al progetto

DECIPHER

ID dell’accordo di sovvenzione: 101138593

DOI

10.3030/101138593

Progetto chiuso

Data della firma CE 28 Agosto 2023

Data di avvio 1 Gennaio 2024

Data di completamento 31 Dicembre 2025

Finanziato da

• European Research Council (ERC)

Costo totale

Nessun dato

Contributo UE

€ 150 000,00

Coordinato da

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Ireland

Periodic Reporting for period 1 - DECIPHER (Decellularised Extracellular Carpets for the Innovative Production of Human Engineered Replicates)

Periodo di rendicontazione: 2024-01-01 al 2025-12-31

Sintesi del contesto e degli obiettivi generali del progetto

Cell-derived matrices are multi-functional biomaterials with very high therapeutic capacity. Despite the very promising data that have been obtained to-date in both preclinical and clinical settings, there is very slow commercial and clinical uptake. It has been argued that the very high cell numbers and the prolonged ex vivo culture periods required to develop them limit their applicability, as the manufacturing costs become too high for the healthcare providers to be able to afford them. As a result, functional therapies do not become available to patients. Prof Zevgolis has pioneered the macromolecular crowding technology in eukaryotic cell culture. Macromolecular crowding, through volume exclusion, enhances and accelerates extracellular matrix deposition. DECIPHER aimed to assess the potential of macromolecular crowding in the development of cell-derived matrices. As part of the technology development work-packages, we developed using macromolecular crowding cell-derived matrices using only a fraction of cells and time that traditional approaches require. Further, the enhanced deposited extracellular matrix acts as a depo of trophic and therapeutic factors that promote physiological healing. The commercial development work-packages confirmed the transformative potential of macromolecular crowding in the development of cell-derived matrices for a diverse range of sectors and markets. DECIPHER will contribute to the commercialisation of cell-derived matrices, increasing the international competitiveness of European-based biotech industries and creating new employment, markets and revenue.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

Work-package 1 and work-package 2 (technology development work-packages): Cell-derived matrices with enhanced deposited extracellular matrix were developed using only a fraction of cells and time that traditional approaches require. The enhanced deposited matrix is associated with enhanced functionality. Further, the materials had within the acceptable limits remaining DNA content, making them safe for use in regenerative medicine sector, as well as the cell culture technologies sector, cellular agriculture sector and drug discovery sector.

Work-package 3, work package 4 and work-package 5 (commercial development work-packages): These commercial work-packages were conducted by an independent entity, experienced in market analysis; customer discovery and validation analysis; and exploitation opportunity and route to market analysis. Their comprehensive report clearly recognises the transformative potential of the DECIPHER project in a range of sectors and markets.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Data obtained from the technological work-packages and information obtained from the commercial work-packages very clear identify the commercial opportunity of the DECIPHER project. The team will now work for the development of a competitive European Innovation Council (EIC) Transition proposal. it is anticipated that a company will be formed in the coming months. Scientific, clinical and commercial leads are already in place.